This protocol addresses a specific subset of endometriosis patients — those who cannot use estrogen-containing combined hormonal contraceptives due to a contraindication or intolerance, and whose prior second-line hormonal treatment did not achieve adequate pain relief.
Estrogen-based combined hormonal contraceptives are not an option for this patient. Estrogen-sparing alternatives, such as progestin-only methods, may be considered in this population; however, this protocol focuses on the escalation step when those and other second-line agents have proven insufficient.
The prior treatment line included a GnRH receptor agonist with add-back therapy, a GnRH receptor antagonist, or danazol. The intended goal of that line — improvement of dysmenorrhea and nonmenstrual pelvic pain — was not reached. This protocol represents the escalation step following that failure.
For severe, refractory endometriosis-related pain in this setting, management involves an aromatase inhibitor, used in combination with a second hormonal agent to address ovarian activity. The specific agent selection, combination, and full clinical sequencing are detailed in the structured protocol.